Fulcrum Therapeutics Acquires Global Rights to GlaxoSmithKline’s Facioscapulohumeral Muscular Dystrophy Therapy

Fulcrum Therapeutics Acquires Global Rights to GlaxoSmithKline’s Facioscapulohumeral Muscular Dystrophy Therapy

Fulcrum Therapeutics announced an exclusive worldwide license agreement with GlaxoSmithKline for development and commercialization of the investigational drug losmapimod. Fulcrum intends to advance losmapimod into a Phase 2b trial in the rare and genetic disease...

Pin It on Pinterest